ASSEMBLY BIOSCIENCES, INC. (ASMB) Form 8-K — Aug 13, 2026
Assembly Biosciences (Nasdaq: ASMB) reported a second-quarter 2026 net loss attributable to common stockholders of $3.9 million, or $0.20 per basic and diluted share, versus a $10.2 million loss, or $1.33 per share, in the year-ago quarter. Collaboration revenue from Gilead rose to $13.4 million from $9.6 million, helped by a $5.1 million cumulative catch-up adjustment under the Gilead collaboration. The company completed a $115 million gross financing during the quarter and held $320.4 million in cash, cash equivalents and marketable securities at June 30, 2026, up from $226.6 million at March 31, 2026.
Key figures
- Revenue
- 13374000
- Revenue Yoy
- Q2 2026 $13.4M vs Q2 2025 $9.6M
- Total Assets
- 330832000
- Cash Position
- 320400000
- Shares Outstanding
- 19850342
- Cash runway
- projected into 2029
- Ga expense q2 2026
- 4801000
- Rd expense q2 2026
- 14917000
- Accumulated deficit
- 844983000
- Prior year q2 net loss
- -$10.2 million ($1.33 per basic and diluted share)
- Total stockholders equity
- 305649000
- Us cost profit share option
- 40%
- Weighted avg shares q2 2025
- 7655854
- Weighted avg shares q2 2026
- 18853646
- Gilead extension payment usd
- 75000000
- Gross financing completed usd
- 115000000
- Gilead extension payment timing
- Q4 2026
- Cumulative catch up revenue adjustment usd
- 5100000
Price after filing
Close on the filing date to close N calendar days later (from $27.27). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.